Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: A Pediatric Oncology Group study

Mark L. Bernstein, Thomas C. Abshire, Bradley H Pollock, Susan Devine, Stuart Toledano, C. Philip Steuber, W. Paul Bowman, George R. Buchanan

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: This study was designed to determine the toxicity of and response to idarubicin and cytosine arabinoside in children and adolescents with acute lymphoblastic leukemia (ALL) who had refractory or recurrent bone marrow disease. Patients and Methods: Patients <21 years of age with ALL in second or later bone marrow relapse or refractory to induction therapy were eligible. Some patients also had concurrent central nervous system (CNS) relapse. Therapy consisted of cytosine arabinoside, 1 g/m2/day given as a 6- h infusion, followed by bolus idarubicin, 5 mg/m2/day, both daily for 6 days. Children achieving remission received maintenance therapy with 3 days of etoposide, 100 mg/m2/day, followed by ifosfamide, 2.8 g/m2/day, alternating every 3 weeks with 3 days of cytosine arabinoside and idarubicin in the dosages described earlier. All courses of therapy were followed by granulocyte colony-stimulating factor (G-CSF). Removal from study to undergo bone marrow transplantation (BMT) was encouraged. Results: Eighty-two patients were entered. There were 14 deaths (nine early), mostly from documented or presumed bacterial or fungal sepsis. Overall, 30 patients achieved complete remission (37%). These were mostly of brief duration only one patient was still alive at 600+ days after BMT. Conclusions: Cytosine arabinoside and idarubicin showed moderate activity in heavily pretreated children with ALL.

Original languageEnglish (US)
Pages (from-to)68-72
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume19
Issue number1
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Idarubicin
Cytarabine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
Bone Marrow Transplantation
Therapeutics
Bone Marrow Diseases
Recurrence
Ifosfamide
Granulocyte Colony-Stimulating Factor
Etoposide
Sepsis
Central Nervous System
Bone Marrow

Keywords

  • Childhood
  • Cytosine arabinoside
  • Idarubicin
  • Recurrent acute lymphoblastic leukemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia : A Pediatric Oncology Group study. / Bernstein, Mark L.; Abshire, Thomas C.; Pollock, Bradley H; Devine, Susan; Toledano, Stuart; Steuber, C. Philip; Bowman, W. Paul; Buchanan, George R.

In: Journal of Pediatric Hematology/Oncology, Vol. 19, No. 1, 1997, p. 68-72.

Research output: Contribution to journalArticle

Bernstein, Mark L. ; Abshire, Thomas C. ; Pollock, Bradley H ; Devine, Susan ; Toledano, Stuart ; Steuber, C. Philip ; Bowman, W. Paul ; Buchanan, George R. / Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia : A Pediatric Oncology Group study. In: Journal of Pediatric Hematology/Oncology. 1997 ; Vol. 19, No. 1. pp. 68-72.
@article{b25c25c33f274a2fa440e1827d0f22f1,
title = "Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: A Pediatric Oncology Group study",
abstract = "Purpose: This study was designed to determine the toxicity of and response to idarubicin and cytosine arabinoside in children and adolescents with acute lymphoblastic leukemia (ALL) who had refractory or recurrent bone marrow disease. Patients and Methods: Patients <21 years of age with ALL in second or later bone marrow relapse or refractory to induction therapy were eligible. Some patients also had concurrent central nervous system (CNS) relapse. Therapy consisted of cytosine arabinoside, 1 g/m2/day given as a 6- h infusion, followed by bolus idarubicin, 5 mg/m2/day, both daily for 6 days. Children achieving remission received maintenance therapy with 3 days of etoposide, 100 mg/m2/day, followed by ifosfamide, 2.8 g/m2/day, alternating every 3 weeks with 3 days of cytosine arabinoside and idarubicin in the dosages described earlier. All courses of therapy were followed by granulocyte colony-stimulating factor (G-CSF). Removal from study to undergo bone marrow transplantation (BMT) was encouraged. Results: Eighty-two patients were entered. There were 14 deaths (nine early), mostly from documented or presumed bacterial or fungal sepsis. Overall, 30 patients achieved complete remission (37{\%}). These were mostly of brief duration only one patient was still alive at 600+ days after BMT. Conclusions: Cytosine arabinoside and idarubicin showed moderate activity in heavily pretreated children with ALL.",
keywords = "Childhood, Cytosine arabinoside, Idarubicin, Recurrent acute lymphoblastic leukemia",
author = "Bernstein, {Mark L.} and Abshire, {Thomas C.} and Pollock, {Bradley H} and Susan Devine and Stuart Toledano and Steuber, {C. Philip} and Bowman, {W. Paul} and Buchanan, {George R.}",
year = "1997",
doi = "10.1097/00043426-199701000-00010",
language = "English (US)",
volume = "19",
pages = "68--72",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia

T2 - A Pediatric Oncology Group study

AU - Bernstein, Mark L.

AU - Abshire, Thomas C.

AU - Pollock, Bradley H

AU - Devine, Susan

AU - Toledano, Stuart

AU - Steuber, C. Philip

AU - Bowman, W. Paul

AU - Buchanan, George R.

PY - 1997

Y1 - 1997

N2 - Purpose: This study was designed to determine the toxicity of and response to idarubicin and cytosine arabinoside in children and adolescents with acute lymphoblastic leukemia (ALL) who had refractory or recurrent bone marrow disease. Patients and Methods: Patients <21 years of age with ALL in second or later bone marrow relapse or refractory to induction therapy were eligible. Some patients also had concurrent central nervous system (CNS) relapse. Therapy consisted of cytosine arabinoside, 1 g/m2/day given as a 6- h infusion, followed by bolus idarubicin, 5 mg/m2/day, both daily for 6 days. Children achieving remission received maintenance therapy with 3 days of etoposide, 100 mg/m2/day, followed by ifosfamide, 2.8 g/m2/day, alternating every 3 weeks with 3 days of cytosine arabinoside and idarubicin in the dosages described earlier. All courses of therapy were followed by granulocyte colony-stimulating factor (G-CSF). Removal from study to undergo bone marrow transplantation (BMT) was encouraged. Results: Eighty-two patients were entered. There were 14 deaths (nine early), mostly from documented or presumed bacterial or fungal sepsis. Overall, 30 patients achieved complete remission (37%). These were mostly of brief duration only one patient was still alive at 600+ days after BMT. Conclusions: Cytosine arabinoside and idarubicin showed moderate activity in heavily pretreated children with ALL.

AB - Purpose: This study was designed to determine the toxicity of and response to idarubicin and cytosine arabinoside in children and adolescents with acute lymphoblastic leukemia (ALL) who had refractory or recurrent bone marrow disease. Patients and Methods: Patients <21 years of age with ALL in second or later bone marrow relapse or refractory to induction therapy were eligible. Some patients also had concurrent central nervous system (CNS) relapse. Therapy consisted of cytosine arabinoside, 1 g/m2/day given as a 6- h infusion, followed by bolus idarubicin, 5 mg/m2/day, both daily for 6 days. Children achieving remission received maintenance therapy with 3 days of etoposide, 100 mg/m2/day, followed by ifosfamide, 2.8 g/m2/day, alternating every 3 weeks with 3 days of cytosine arabinoside and idarubicin in the dosages described earlier. All courses of therapy were followed by granulocyte colony-stimulating factor (G-CSF). Removal from study to undergo bone marrow transplantation (BMT) was encouraged. Results: Eighty-two patients were entered. There were 14 deaths (nine early), mostly from documented or presumed bacterial or fungal sepsis. Overall, 30 patients achieved complete remission (37%). These were mostly of brief duration only one patient was still alive at 600+ days after BMT. Conclusions: Cytosine arabinoside and idarubicin showed moderate activity in heavily pretreated children with ALL.

KW - Childhood

KW - Cytosine arabinoside

KW - Idarubicin

KW - Recurrent acute lymphoblastic leukemia

UR - http://www.scopus.com/inward/record.url?scp=0030899108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030899108&partnerID=8YFLogxK

U2 - 10.1097/00043426-199701000-00010

DO - 10.1097/00043426-199701000-00010

M3 - Article

C2 - 9065722

AN - SCOPUS:0030899108

VL - 19

SP - 68

EP - 72

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 1

ER -